Vitiligo
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Vitiligo na yatsunsu ya fi wuya a bi da su fiye da sauran wurare. Baya ga rashin kyawun kwalliya, vitiligo na al'ada ne kuma baya yaduwa. A cikin dermatology, magani mafi inganci shine phototherapy ko laser (excimer) sau 2-3 a mako don akalla shekara 1. Idan ba za ku iya zuwa asibiti akai-akai don dalilai na kuɗi ko kuma saboda kuna aiki ba, kuna iya gwada injin phototherapy wanda aka yarda don amfani da gida.
vitiligo ido
Vitiligo a hannu
References
Vitiligo cuta ce ta fata ta gama gari wacce ke haifar da facin farin fata saboda asarar melanocytes. Bincike na baya-bayan nan ya nuna cutar ce mai saurin kamuwa da cuta. Duk da yake ana yawan ganin shi a matsayin batun kwaskwarima, yana iya yin tasiri sosai ga lafiyar kwakwalwa da rayuwar yau da kullum. A shekara ta 2011, masana sun ware nau'i mai suna segmental vitiligo daban da sauran.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Marasa lafiya na vitiligo masu aiki suna da zaɓuɓɓukan magani da yawa, kamar su glucocorticoids na tsarin, phototherapy, da ƙwayoyin rigakafi na tsarin. Marasa lafiya marasa ƙarfi na vitiligo na iya samun sauƙi daga corticosteroids na sama, masu hana calcineurin na sama, phototherapy, da hanyoyin dasawa. Ci gaba na baya-bayan nan a fahimtar hanyoyin vitiligo sun haifar da haɓaka hanyoyin kwantar da hankali. A halin yanzu, masu hanawa na JAK sune mafi alƙawarin, suna ba da haƙuri mai kyau da sakamako na aiki, duk da haɗarin kunna cututtukan cututtukan da ke ɓoye da kuma illar tsarin da ke tattare da sauran wakilai na rigakafi. Ci gaba da bincike na nufin gano mahimman cytokines da ke cikin haɓakar vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Kashe waɗannan cytokines ya nuna alƙawarin a cikin ƙirar dabba da wasu marasa lafiya. Bugu da kari, ana gudanar da bincike kan miRNA-based therapeutics da adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ba a san maganin vitiligo ba. Ga wadanda ke da fata mai haske, maganin rana da kayan shafa sune duk abin da aka saba ba da shawarar. Sauran zaɓuɓɓukan magani na iya haɗawa da kirim na steroid ko phototherapy.
○ Magani
#Phototherapy
#Excimer laser
#Tacrolimus ointment